DARE-19 Principal Investigator Mikhail Kosiborod, MD, will provide the first look at a subgroup analysis of type 2 diabetes patients who are at higher risk for developing serious complications from COVID-19 in a session beginning at 2:15 p.m. ET.
Coming up Sunday afternoon: DARE-19 results provide insight into SGLT2 inhibitor use in patients with type 2 diabetes and COVID-19
